The win is Abbott’s third in a row in federal court in Chicago where hundreds of cases over specialized formulas for preterm ...

Abbott Laboratories (NYSE:ABT) traded ~3% lower in the premarket on Wednesday after the MedTech giant’s Q3 2025 results ...

Abbott stock skidded Wednesday after the S&P 500 health giant missed the Street's third-quarter sales forecast, but met ...

The stock's fall snapped a two-day winning streak.

Abbott Labs reported 6.9% sales growth in Q3 2025, led by medical devices and nutrition, while reaffirming full-year guidance ...

Abbott Laboratories (NYSE:ABT) develops, manufactures, and sells healthcare products, including pharmaceuticals, diagnostics, ...

According to a filing with the Securities and Exchange Commission dated October 14, 2025, CCLA Investment Management ...

Walmart will become the first U.S. retailer to sell Abbott Laboratories' over-the-counter continuous glucose monitor Lingo in ...

Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration ...

Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that ...

Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4 ...

Abbott Laboratories (ABT) reports robust earnings with significant contributions from medical devices and new product ...